PURPOSE: To assess the patterns of failure in the treatment of early-stage squamous cell carcinoma of the glottic larynx. PATIENTS AND METHODS: Between 1983-2000, 122 consecutive patients treated for early laryngeal cancer (UICC T1N0 and T2N0) by radical radiation therapy (RT) were retrospectively studied. Male-to-female ratio was 106 : 16, and median age 62 years (35-92 years). There were 68 patients with T1a, 18 with T1b, and 36 with T2 tumors. Diagnosis was made by biopsy in 104 patients, and by laser vaporization or stripping in 18. Treatment planning consisted of three-dimensional (3-D) conformal RT in 49 (40%) patients including nine patients irradiated using arytenoid protection. A median dose of 70 Gy (60-74 Gy) was given (2 Gy/fraction) over a median period of 46 days (21-79 days). Median follow-up period was 85 months. RESULTS: The 5-year overall, cancer-specific, and disease-free survival amounted to 80%, 94%, and 70%, respectively. 5-year local control was 83%. Median time to local recurrence in 19 patients was 13 months (5-58 months). Salvage treatment consisted of surgery in 17 patients (one patient refused salvage and one was inoperable; total laryngectomy in eleven, and partial laryngectomy or cordectomy in six patients). Six patients died because of laryngeal cancer. Univariate analyses revealed that prognostic factors negatively influencing local control were anterior commissure extension, arytenoid protection, and total RT dose < 66 Gy. Among the factors analyzed, multivariate analysis (Cox model) demonstrated that anterior commissure extension, arytenoid protection, and male gender were the worst independent prognostic factors in terms of local control. CONCLUSION: For early-stage laryngeal cancer, outcome after RT is excellent. In case of anterior commissure extension, surgery or higher RT doses are warranted. Because of a high relapse risk, arytenoid protection should not be attempted.
PURPOSE: To assess the patterns of failure in the treatment of early-stage squamous cell carcinoma of the glottic larynx. PATIENTS AND METHODS: Between 1983-2000, 122 consecutive patients treated for early laryngeal cancer (UICC T1N0 and T2N0) by radical radiation therapy (RT) were retrospectively studied. Male-to-female ratio was 106 : 16, and median age 62 years (35-92 years). There were 68 patients with T1a, 18 with T1b, and 36 with T2 tumors. Diagnosis was made by biopsy in 104 patients, and by laser vaporization or stripping in 18. Treatment planning consisted of three-dimensional (3-D) conformal RT in 49 (40%) patients including nine patients irradiated using arytenoid protection. A median dose of 70 Gy (60-74 Gy) was given (2 Gy/fraction) over a median period of 46 days (21-79 days). Median follow-up period was 85 months. RESULTS: The 5-year overall, cancer-specific, and disease-free survival amounted to 80%, 94%, and 70%, respectively. 5-year local control was 83%. Median time to local recurrence in 19 patients was 13 months (5-58 months). Salvage treatment consisted of surgery in 17 patients (one patient refused salvage and one was inoperable; total laryngectomy in eleven, and partial laryngectomy or cordectomy in six patients). Six patients died because of laryngeal cancer. Univariate analyses revealed that prognostic factors negatively influencing local control were anterior commissure extension, arytenoid protection, and total RT dose < 66 Gy. Among the factors analyzed, multivariate analysis (Cox model) demonstrated that anterior commissure extension, arytenoid protection, and male gender were the worst independent prognostic factors in terms of local control. CONCLUSION: For early-stage laryngeal cancer, outcome after RT is excellent. In case of anterior commissure extension, surgery or higher RT doses are warranted. Because of a high relapse risk, arytenoid protection should not be attempted.
Authors: Patrick J Bradley; Alessandra Rinaldo; Carlos Suárez; Ashok R Shaha; C René Leemans; Johannes A Langendijk; Snehal G Patel; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2006-08-15 Impact factor: 2.503
Authors: Nicola Dinapoli; Claudio Parrilla; Jacopo Galli; Rosa Autorino; Francesco Miccichè; Francesco Bussu; Mario Balducci; Lucia D'Alatri; Raffaella Marchese; Mario Rigante; Giuseppe Di Lella; Luca Liberati; Giovanni Almadori; Gaetano Paludetti; Vincenzo Valentini Journal: Strahlenther Onkol Date: 2010-11-08 Impact factor: 3.621
Authors: David I Rosenthal; Clifton D Fuller; Jerry L Barker; Bryan Mason; John A Garcia; Jan S Lewin; F Christopher Holsinger; C Richard Stasney; Steven J Frank; David L Schwartz; William H Morrison; Adam S Garden; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2009-08-11 Impact factor: 7.038
Authors: Olgun Elicin; Ekin Ermiş; Christoph Oehler; Daniel M Aebersold; Francesca Caparrotti; Frank Zimmermann; Gabriela Studer; Guido Henke; Lukas Adam; Lukas Anschuetz; Mahmut Ozsahin; Matthias Guckenberger; Mohamed Shelan; Nuri Kaydıhan; Oliver Riesterer; Robin J D Prestwich; Thierry Spielmann; Roland Giger; Mehmet Şen Journal: Front Oncol Date: 2019-09-20 Impact factor: 6.244
Authors: S Mark Taylor; Paul Kerr; Kevin Fung; Mankavil K Aneeshkumar; Derek Wilke; Yida Jiang; John Scott; Judith Phillips; Robert D Hart; Jonathan R B Trites; Matthew H Rigby Journal: J Otolaryngol Head Neck Surg Date: 2013-03-19
Authors: Martine Hendriksma; Marc A P van Ruler; Berit M Verbist; Martin A de Jong; Ton P M Langeveld; Peter Paul G van Benthem; Elisabeth V Sjögren Journal: Cancers (Basel) Date: 2019-09-06 Impact factor: 6.639